Stock PTN PALATIN TECHNOLOGIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Palatin Technologies, Inc.

Equities

PTN

US6960775020

Biotechnology & Medical Research

Market Closed - Nyse
Other stock markets
 04:00:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
1.82 USD +5.81% Intraday chart for Palatin Technologies, Inc. -1.09% -54.27%
Apr. 08 Palatin Announces Phase 3 Pl9643 Melody-1 Dry Eye Disease Clinical Data Results Presented At American Society of Cataract and Refractive Surgery 2024 CI
Feb. 28 Sector Update: Health Care Stocks Decline Late Afternoon MT

Valuation

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Capitalization 1 250 117.4 140.3 65.04 24.2 29.37 - -
Enterprise Value (EV) 1 250 117.4 140.3 65.04 24.2 29.37 29.37 29.37
P/E ratio 7.25 x -5.12 x -4.36 x -1.85 x -0.83 x -1.1 x -1.9 x -4.67 x
Yield - - - - - - - -
Capitalization / Revenue 4.15 x 995 x -744 x 44.3 x 4.99 x 6.84 x 3.93 x 0.68 x
EV / Revenue 4.15 x 995 x -744 x 44.3 x 4.99 x 6.84 x 3.93 x 0.68 x
EV / EBITDA 6,983,925 x -4,985,872 x -4,209,954 x - -752,220 x - - -
EV / FCF - - - - - - - -
FCF Yield - - - - - - - -
Price to Book - - - - - - - -
Nbr of stocks (in thousands) 8,622 9,170 9,202 9,271 11,523 16,137 - -
Reference price 2 29.00 12.80 15.25 7.015 2.100 1.820 1.820 1.820
Announcement Date 9/12/19 9/25/20 9/28/21 9/22/22 9/28/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net sales 1 60.3 0.118 -0.1886 1.468 4.854 4.295 7.479 43.06
EBITDA 35.8 -23.54 -33.33 - -32.17 - - -
EBIT 1 35.74 -23.61 -33.38 -36.59 -32.46 -20.71 -24.69 -12.37
Operating Margin 59.28% -20,007.44% 17,701.01% -2,491.62% -668.75% -482.32% -330.14% -28.73%
Earnings before Tax (EBT) 1 35.77 -22.43 -33.6 -36.2 -32.22 -29.04 -24.45 -12.17
Net income 1 35.77 -22.43 -33.6 -36.2 -27.54 -27.28 -21.23 -12.17
Net margin 59.32% -19,006.71% 17,813.63% -2,465.05% -567.44% -635.22% -283.83% -28.26%
EPS 2 4.000 -2.500 -3.500 -3.790 -2.530 -1.660 -0.9600 -0.3900
Free Cash Flow - - - - - - - -
FCF margin - - - - - - - -
FCF Conversion (EBITDA) - - - - - - - -
FCF Conversion (Net income) - - - - - - - -
Dividend per Share - - - - - - - -
Announcement Date 9/12/19 9/25/20 9/28/21 9/22/22 9/28/23 - - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: June 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1 2025 Q2 2025 Q3
Net sales 1 0.1595 0.3221 0.2161 0.7707 0.8696 1.026 1.196 1.762 2.106 2.034 0.0807 0.0873 0.314 0.346 7.88
EBITDA 1 -7.203 -8.424 -7.776 - -8.693 -6.544 -7.223 -10.74 -6.022 1.258 -10.7 -11 - - -
EBIT 1 -7.216 -8.451 -7.82 -13.1 -8.753 -6.614 -7.301 -10.82 -6.109 1.173 -8.228 -7.55 -6.219 -6.611 0.47
Operating Margin -4,524.55% -2,623.45% -3,618.88% -1,699.81% -1,006.46% -644.39% -610.64% -613.99% -290.07% 57.67% -10,200.2% -8,645.37% -1,980.57% -1,910.69% 5.96%
Earnings before Tax (EBT) 1 -7.113 -8.686 -7.632 -12.77 -8.255 -6.099 -7.148 -10.71 -5.888 -7.844 -8.977 -8.623 -6.171 -6.562 0.519
Net income 1 -7.113 -8.686 -7.632 -12.77 -8.255 -1.424 -7.148 -10.71 -5.888 -7.844 -8.394 -8.033 -6.171 -6.562 0.519
Net margin -4,459.88% -2,696.49% -3,531.51% -1,656.54% -949.28% -138.74% -597.81% -608.11% -279.6% -385.62% -10,405.36% -9,198.06% -1,965.29% -1,896.53% 6.59%
EPS 2 -0.7500 -1.000 -0.7500 -1.340 -0.8600 -0.1300 -0.6300 -0.9100 -0.4800 -0.5600 -0.4967 -0.4300 -0.2700 -0.2600 0.0200
Dividend per Share - - - - - - - - - - - - - - -
Announcement Date 11/15/21 2/14/22 5/16/22 9/22/22 11/14/22 2/14/23 5/15/23 9/28/23 11/14/23 2/14/24 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: June 2019 2020 2021 2022 2023 2024 2025 2026
Net Debt - - - - - - - -
Net Cash position - - - - - - - -
Leverage (Debt/EBITDA) - - - - - - - -
Free Cash Flow - - - - - - - -
ROE (net income / shareholders' equity) - - - - - - - -
ROA (Net income/ Total Assets) - - - - - - - -
Assets 1 - - - - - - - -
Book Value Per Share - - - - - - - -
Cash Flow per Share - - - - - - - -
Capex 1 - 0.06 0.01 0.26 0.43 0.04 0.19 -
Capex / Sales - 53.29% -3.03% 17.8% 8.94% 0.88% 2.55% -
Announcement Date 9/12/19 9/25/20 9/28/21 9/22/22 9/28/23 - - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Ratings for Palatin Technologies, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
1.82 USD
Average target price
9.333 USD
Spread / Average Target
+412.82%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
PALATIN TECHNOLOGIES, INC. Stock Palatin Technologies, Inc.
-54.27% 29.37M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. PTN Stock
  4. Financials Palatin Technologies, Inc.